Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
5/13/2026, 12:00:00 AM
Leerink Partners upgraded Johnson & Johnson stock to 'Outperform' from 'Market Perform' and raised its price target to $265 from $252, citing promising growth forecasts for new products Icotyde and Inlexzo; price impact estimated at 5% due to positive analyst sentiment forecasted.
Korean Translation
리링크 파트너스가 신제품 아이코타이드와 인렉조의 유망한 성장 전망을 근거로 존슨앤드존슨의 투자의견을 상향 조정하고 목표 주가를 인상함. 긍정적인 분석가 의견에 따라 약 5%의 주가 영향이 전망됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
5/27/2026, 12:00:00 AM